Document Detail

Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.
MedLine Citation:
PMID:  23617249     Owner:  NLM     Status:  MEDLINE    
Tumor microenvironment (TME) refers to the dynamic cellular and extra-cellular components surrounding tumor cells at each stage of the carcinogenesis. TME has now emerged as an integral and inseparable part of the carcinogenesis that plays a critical role in tumor growth, angiogenesis, epithelial to mesenchymal transition (EMT), invasion, migration and metastasis. Besides its vital role in carcinogenesis, TME is also a better drug target because of its relative genetic stability with lesser probability for the development of drug-resistance. Several drugs targeting the TME (endothelial cells, macrophages, cancer-associated fibroblasts, or extra-cellular matrix) have either been approved or are in clinical trials. Recently, non-steroidal anti-inflammatory drugs targeting inflammation were reported to also prevent several cancers. These exciting developments suggest that cancer chemopreventive strategies targeting both tumor and TME would be better and effective towards preventing, retarding or reversing the process of carcinogenesis. Here, we have reviewed the effect of a well established hepatoprotective and chemopreventive agent silibinin on cellular (endothelial, fibroblast and immune cells) and non-cellular components (cytokines, growth factors, proteinases etc.) of the TME. Silibinin targets TME constituents as well as their interaction with cancer cells, thereby inhibiting tumor growth, angiogenesis, inflammation, EMT, and metastasis. Silibinin is already in clinical trials, and based upon completed studies we suggest that its chemopreventive effectiveness should be verified through its effect on biological end points in both tumor and TME. Overall, we believe that the chemopreventive strategies targeting both tumor and TME have practical and translational utility in lowering the cancer burden.
Gagan Deep; Rajesh Agarwal
Related Documents :
17982629 - Over-expression of 14-3-3sigma in budding colorectal cancer cells modulates cell migrat...
11857029 - Gene therapy of melanoma pulmonary metastasis by intramuscular injection of plasmid dna...
12912969 - Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder can...
10910049 - Reproductive state of rat mammary gland stroma modulates human breast cancer cell migra...
10811139 - Aspirin inhibits tumor cell invasiveness induced by epstein-barr virus latent membrane ...
24015299 - Her2 as a promising target for cytotoxicity t cells in human melanoma therapy.
8095979 - Aggressive oligodendroglioma predicted by chromosome 10 restriction fragment length pol...
15777889 - Radiofrequency ablation for malignant liver tumor.
195239 - The brenner tumor: a clinicopathologic review.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current cancer drug targets     Volume:  13     ISSN:  1873-5576     ISO Abbreviation:  Curr Cancer Drug Targets     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-07-03     Completed Date:  2014-01-30     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  101094211     Medline TA:  Curr Cancer Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  486-99     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antioxidants / therapeutic use*
Neoplasms / drug therapy*
Silymarin / therapeutic use*
Translational Medical Research*
Tumor Microenvironment / drug effects*
Grant Support
Reg. No./Substance:
0/Antioxidants; 0/Silymarin; 4RKY41TBTF/silybin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear ...
Next Document:  Effect of Vildagliptin on Glucose and Insulin Concentrations During a 24-Hour Period in Type 2 Diabe...